Has Moderna Stock Already Peaked?
Moderna (NASDAQ: MRNA) has been one of the hottest healthcare stocks of the past year, soaring more than 400% and eclipsing the S&P 500's 55% gains over that time frame. The company's coronavirus vaccine, mRNA-1273, which the U.S. Food and Drug Administration (FDA) issued emergency use authorization (EUA) for in December 2020, is what has gotten investors so excited about the stock as it will generate billions in revenue for the company.
The stock hit an all-time high of $189.26 in early February. But since then, the FDA has issued another EUA for Johnson & Johnson's COVID-19 vaccine, while others, including those from Novavax and AstraZeneca, could also get the green light soon. Today, Moderna's stock is trading around $145, and many investors may be worried that it is too late to buy the stock -- are they right?
Image source: Getty Images.
Source Fool.com
